Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.

导出 LinkOut

翻译打印收藏纠错

作者： Victoria,Furer ^[1] ; Tali,Eviatar ^[2] ; Devy,Zisman ^[3] ; Hagit,Peleg ^[2] ; Daphna,Paran ^[4] ; David,Levartovsky ^[5] ; Michael,Zisapel ^[6] ; Ofir,Elalouf ^[3] ; Ilana,Kaufman ^[2] ; Roni,Meidan ^[3] ; Adi,Broyde ^[3] ; Ari,Polachek ^[3] ; Jonathan,Wollman ^[2] ; Ira,Litinsky ^[3] ; Katya,Meridor ^[2] ; Hila,Nochomovitz ^[2] ; Adi,Silberman ^[7] ; Dana,Rosenberg ^[3] ; Joy,Feld ^[2] ; Amir,Haddad ^[3] ; Tal,Gazzit ^[2] ; Muna,Elias ^[3] ; Nizar,Higazi ^[2] ; Fadi,Kharouf ^[3] ; Gabi,Shefer ^[2] ; Orly,Sharon ^[3] ; Sara,Pel ^[2] ; Sharon,Nevo ^[3] ; Ori,Elkayam ^[2]

作者单位： Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel furer.rheum@gmail.com. ^[1] Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel. ^[2] Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. ^[3] Rheumatology Unit, Carmel Hospital, Haifa, Israel. ^[4] Medicine, Technion Israel Institute of Technology, Haifa, Israel. ^[5] Rheumatology Unit, Hadassah University Hospital, Jerusalem, Israel. ^[6] Internal Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. ^[7] The Hebrew University of Jerusalem Faculty of Medicine, Jerusalem, Jerusalem, Israel. ^[8] Endocrinology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. ^[9]

关键词 Covid-19 biological therapy methotrexate rituximab vaccination